{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:44:00Z","timestamp":1791233040990,"version":"4.1.0"},"reference-count":253,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Biochemistry and Biotechnology of the University of Thessaly"},{"id":[{"id":"https:\/\/ror.org\/04v4g9h31","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Non-coding RNAs (ncRNAs) are increasingly recognized as important regulators of cancer biology. Long non-coding RNAs (lncRNAs), defined as transcripts longer than 200 nucleotides, gain particular attention due to their cancer-specific expression patterns and functional roles in tumor progression, metastasis and therapeutic resistance. Although lncRNAs have been extensively studied as diagnostic, prognostic and predictive biomarkers, growing evidence indicates that they can also act as active mediators of therapeutic resistance, supporting their potential as therapeutic candidates. Here, we summarize how lncRNAs contribute to resistance against radiotherapy, chemotherapy, immunotherapy and targeted therapy, highlighting their molecular mechanisms. Next, we discuss RNA-based therapeutics as a strategy to target disease-relevant transcripts, focusing on antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNA (miRNA) mimics and antimiRs, as well as approved RNA therapeutic agents, oncology-focused candidates in clinical development and emerging preclinical approaches directed against lncRNAs or lncRNA-controlled regulatory axes. Finally, we examine delivery platforms, including lipid-based nanovectors, extracellular vesicles, polymeric systems and other approaches designed to overcome key translational barriers, such as RNA instability, off-target effects, immune activation, renal clearance and inefficient tumor-specific delivery. By connecting lncRNA-mediated resistance mechanisms with RNA therapeutic strategies and delivery technologies, this review highlights lncRNA-directed RNA therapeutics as a promising yet developing approach in oncology.<\/jats:p>","DOI":"10.3390\/cancers18152497","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:15:22Z","timestamp":1785834922000},"page":"2497","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting lncRNAs to Overcome Cancer Therapy Resistance: Advances in RNA Therapeutics and Delivery Strategies"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0274-8627","authenticated-orcid":false,"given":"Christos","family":"Drosos","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Biotechnology, University of Thessaly, Biopolis, Mezourlo, 41500 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0805-6195","authenticated-orcid":false,"given":"Athina","family":"Kapsi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Biotechnology, University of Thessaly, Biopolis, Mezourlo, 41500 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthi","family":"Nikolaidou","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Biotechnology, University of Thessaly, Biopolis, Mezourlo, 41500 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8648-9908","authenticated-orcid":false,"given":"Antonis","family":"Giakountis","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Biotechnology, University of Thessaly, Biopolis, Mezourlo, 41500 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-024-01640-8","article-title":"Global burden of cancer and associated risk factors in 204 countries and territories, 1980\u20132021: A systematic analysis for the GBD 2021","volume":"17","author":"Wu","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_3","first-page":"e1764","article-title":"Technological advancements in cancer diagnostics: Improvements and limitations","volume":"6","author":"Pulumati","year":"2023","journal-title":"Cancer Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"109979","DOI":"10.1016\/j.isci.2024.109979","article-title":"Hallmarks of cancer resistance","volume":"27","author":"Tufail","year":"2024","journal-title":"iScience"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the mechanisms and challenges of cancer drug resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41568-025-00824-9","article-title":"Acquired resistance in cancer: Towards targeted therapeutic strategies","volume":"25","author":"Soragni","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41392-022-00975-3","article-title":"Targeting non-coding RNAs to overcome cancer therapy resistance","volume":"7","author":"Chen","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41422-024-00975-8","article-title":"Coding, or non-coding, that is the question","volume":"34","author":"Poliseno","year":"2024","journal-title":"Cell Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1016\/j.cell.2024.10.024","article-title":"Small and long non-coding RNAs: Past, present, and future","volume":"187","author":"Chen","year":"2024","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.tcb.2022.01.006","article-title":"LncRNAs in human cancers: Signal from noise","volume":"32","author":"Adnane","year":"2022","journal-title":"Trends Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.3192","article-title":"The landscape of long noncoding RNAs in the human transcriptome","volume":"47","author":"Iyer","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00438-016-1179-y","article-title":"Characters, functions and clinical perspectives of long non-coding RNAs","volume":"291","author":"Wu","year":"2016","journal-title":"Mol. Genet. Genom."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/nm.3981","article-title":"The emerging role of lncRNAs in cancer","volume":"21","author":"Huarte","year":"2015","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jiao, J., Zhao, Y., Li, Q., Jin, S., and Liu, Z. (2024). LncRNAs in tumor metabolic reprogramming and tumor microenvironment remodeling. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1467151"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.tips.2020.08.004","article-title":"Paving the Road for RNA Therapeutics","volume":"41","author":"Dammes","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-based drug design: Considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/nat.2022.0004","article-title":"Delivery of RNA Therapeutics: The Great Endosomal Escape!","volume":"32","author":"Dowdy","year":"2022","journal-title":"Nucleic Acid. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zhou, X., Ao, X., Jia, Z., Li, Y., Kuang, S., Du, C., Zhang, J., Wang, J., and Liu, Y. (2022). Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.951864"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"113294","DOI":"10.1016\/j.yexcr.2022.113294","article-title":"Long non-coding RNAs (lncRNAs); roles in tumorigenesis and potentials as biomarkers in cancer diagnosis","volume":"418","author":"Najafi","year":"2022","journal-title":"Exp. Cell Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ncrna.2022.02.004","article-title":"Long noncoding RNAs as promising biomarkers in cancer","volume":"7","author":"Beylerli","year":"2022","journal-title":"Noncoding RNA Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-019-0748-z","article-title":"Noncoding RNAs in cancer therapy resistance and targeted drug development","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_22","first-page":"139","article-title":"Principles of cancer treatment by radiotherapy","volume":"42","author":"Vaidya","year":"2024","journal-title":"Surgery"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Podralska, M., Ciesielska, S., Kluiver, J., van den Berg, A., Dzikiewicz-Krawczyk, A., and Slezak-Prochazka, I. (2020). Non-Coding RNAs in Cancer Radiosensitivity: MicroRNAs and lncRNAs as Regulators of Radiation-Induced Signaling Pathways. Cancers, 12.","DOI":"10.3390\/cancers12061662"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41418-022-01049-1","article-title":"A novel long noncoding RNA SP100-AS1 induces radioresistance of colorectal cancer via sponging miR-622 and stabilizing ATG3","volume":"30","author":"Zhou","year":"2023","journal-title":"Cell Death Differ."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41419-020-03302-2","article-title":"LncRNA linc00312 suppresses radiotherapy resistance by targeting DNA-PKcs and impairing DNA damage repair in nasopharyngeal carcinoma","volume":"12","author":"Guo","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101034","DOI":"10.1016\/j.neo.2024.101034","article-title":"LncRNA HOTAIRM1 promotes radioresistance in nasopharyngeal carcinoma by modulating FTO acetylation-dependent alternative splicing of CD44","volume":"56","author":"Mi","year":"2024","journal-title":"Neoplasia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41419-025-08058-1","article-title":"Cancer-associated fibroblast-induced lncRNA WARS2-IT1 confers radioresistance of colorectal cancer via enhancing HIF-1alpha stability","volume":"16","author":"Li","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00262-021-03013-3","article-title":"Chemotherapy: A double-edged sword in cancer treatment","volume":"71","author":"Behranvand","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1007\/s11033-020-05609-x","article-title":"Emerging role of long non-coding RNAs in cancer chemoresistance: Unravelling the multifaceted role and prospective therapeutic targeting","volume":"47","author":"Singh","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/s41417-023-00595-1","article-title":"LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK\/ERK signaling","volume":"30","author":"Shi","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41419-025-07374-w","article-title":"Long noncoding RNA GDIL acts as a scaffold for CHAC1 and XRN2 to promote platinum resistance of colorectal cancer through inhibition of glutathione degradation","volume":"16","author":"Deng","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"216828","DOI":"10.1016\/j.canlet.2024.216828","article-title":"LncRNA GAS6-AS1 contributes to 5-fluorouracil resistance in colorectal cancer by facilitating the binding of PCBP1 with MCM3","volume":"589","author":"Zhu","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/ars.2023.0298","article-title":"A Novel lncRNA FUAT1\/TNS4 Axis Confers Chemoresistance by Suppressing Reactive Oxygen Species-Mediated Apoptosis in Gastric Cancer","volume":"41","author":"Liu","year":"2024","journal-title":"Antioxid. Redox Signal"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"103362","DOI":"10.1016\/j.redox.2024.103362","article-title":"LncRNA-HMG incites colorectal cancer cells to chemoresistance via repressing p53-mediated ferroptosis","volume":"77","author":"Xin","year":"2024","journal-title":"Redox Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/s41388-023-02657-y","article-title":"LncRNA CACClnc promotes chemoresistance of colorectal cancer by modulating alternative splicing of RAD51","volume":"42","author":"Zhang","year":"2023","journal-title":"Oncogene"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41401-025-01653-0","article-title":"Long non-coding RNA STMN1P2 promotes breast cancer doxorubicin resistance by inhibiting pyroptosis through the hnRNPU-EZH2-TARF6-MALT1-caspase-1 pathway","volume":"47","author":"Jin","year":"2026","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13046-025-03330-w","article-title":"Exosome-transmitted LUCAT1 promotes stemness transformation and chemoresistance in bladder cancer by binding to IGF2BP2","volume":"44","author":"Zhan","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e2207257","DOI":"10.1002\/advs.202207257","article-title":"Targeting lncRNA DDIT4-AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy","volume":"10","author":"Jiang","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"147230","DOI":"10.1016\/j.gene.2023.147230","article-title":"Exosomal lncRNA NEAT1 induces paclitaxel resistance in breast cancer cells and promotes cell migration by targeting miR-133b","volume":"860","author":"Wei","year":"2023","journal-title":"Gene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1158\/1535-7163.MCT-14-0636","article-title":"Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance","volume":"14","author":"Gines","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1111\/cas.14532","article-title":"5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes","volume":"111","author":"Blondy","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: Pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet Genom."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","article-title":"Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer","volume":"741","author":"Monteiro","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10495-022-01750-z","article-title":"Mechanisms of cancer cell death induction by paclitaxel: An updated review","volume":"27","author":"Zhao","year":"2022","journal-title":"Apoptosis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Arshi, A., Mahmoudi, E., Raeisi, F., Dehghan Tezerjani, M., Bahramian, E., Ahmed, Y., and Peng, C. (2024). Exploring potential roles of long non-coding RNAs in cancer immunotherapy: A comprehensive review. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1446937"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Eptaminitaki, G.C., Wolff, N., Stellas, D., Sifakis, K., and Baritaki, S. (2021). Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and Immunotherapy. Cells, 10.","DOI":"10.3390\/cells10123313"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s10020-025-01336-w","article-title":"Targeting LINC02544\/miR-497-5p\/CAPRIN1 axis via exosome-based siRNA to overcome immunotherapy resistance in triple-negative breast cancer","volume":"31","author":"Lian","year":"2025","journal-title":"Mol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"eadr9131","DOI":"10.1126\/scisignal.adr9131","article-title":"The lncRNA EPIC1 suppresses dsRNA-induced type I IFN signaling and is a therapeutic target to enhance TNBC response to PD-1 inhibition","volume":"18","author":"Pattarayan","year":"2025","journal-title":"Sci. Signal."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41590-019-0400-7","article-title":"Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression","volume":"20","author":"Hu","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13058-023-01720-6","article-title":"Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing HER-2 protein expression and mRNA stability by binding to HUR","volume":"25","author":"Liu","year":"2023","journal-title":"Breast Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41419-025-07657-2","article-title":"PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer","volume":"16","author":"Zhao","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7150\/jca.65687","article-title":"LncRNA UCA1 mediates Cetuximab resistance in Colorectal Cancer via the MiR-495 and HGF\/c-MET Pathways","volume":"13","author":"Yuan","year":"2022","journal-title":"J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.7150\/thno.99197","article-title":"Decreased lncRNA HNF4A-AS1 facilitates resistance to sorafenib-induced ferroptosis of hepatocellular carcinoma by reprogramming lipid metabolism","volume":"14","author":"Zhao","year":"2024","journal-title":"Theranostics"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12943-024-01988-y","article-title":"Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC","volume":"23","author":"Chan","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"eadi3821","DOI":"10.1126\/sciadv.adi3821","article-title":"LncRNA EILA promotes CDK4\/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein","volume":"9","author":"Cai","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics\u2014Challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Hossam Abdelmonem, B., Kamal, L.T., Wardy, L.W., Ragheb, M., Hanna, M.M., Elsharkawy, M., and Abdelnaser, A. (2025). Non-coding RNAs: Emerging biomarkers and therapeutic targets in cancer and inflammatory diseases. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1534862"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41573-025-01237-x","article-title":"RNA chemistry and therapeutics","volume":"24","author":"Wang","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003495-199957030-00010","article-title":"Fomivirsen","volume":"57","author":"Perry","year":"1999","journal-title":"Drugs"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: First Global Approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: First Global Approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: First Approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","article-title":"Volanesorsen: First Global Approval","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1186\/s13023-025-04042-2","article-title":"Concurrent nanotherapeutics and regulatory updates for the management of amyotrophic lateral sclerosis: A focused review for orphan drug (Tofersen)","volume":"20","author":"Kumar","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-024-02008-5","article-title":"Eplontersen: First Approval","volume":"84","author":"Nie","year":"2024","journal-title":"Drugs"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40265-025-02166-0","article-title":"Olezarsen: First Approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40265-024-02080-x","article-title":"Imetelstat: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40265-025-02257-y","article-title":"Donidalorsen: First Approval","volume":"86","author":"Syed","year":"2026","journal-title":"Drugs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: First Global Approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: First Approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: First Approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: First Approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: First Approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","article-title":"Nedosiran: First Approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"101555","DOI":"10.1016\/j.xcrm.2024.101555","article-title":"Advancements in clinical RNA therapeutics: Present developments and prospective outlooks","volume":"5","author":"Saw","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e114760","DOI":"10.15252\/embj.2023114760","article-title":"RNA-based medicine: From molecular mechanisms to therapy","volume":"42","author":"Sparmann","year":"2023","journal-title":"EMBO J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2024.0069","article-title":"It is Time to Revisit miRNA Therapeutics","volume":"35","author":"Corey","year":"2025","journal-title":"Nucleic Acid. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: An overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/bs.pmbts.2024.01.003","article-title":"RNA therapeutics in cancer treatment","volume":"203","author":"Nguyen","year":"2024","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: An overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"114196","DOI":"10.1016\/j.bcp.2020.114196","article-title":"Antisense drug discovery and development technology considered in a pharmacological context","volume":"189","author":"Crooke","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Collotta, D., Bertocchi, I., Chiapello, E., and Collino, M. (2023). Antisense oligonucleotides: A novel Frontier in pharmacological strategy. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1304342"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1038\/s41467-020-17093-9","article-title":"Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression","volume":"11","author":"Lim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jimd.12251","article-title":"Opportunities and challenges for antisense oligonucleotide therapies","volume":"44","author":"Kuijper","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/17460441.2026.2652440","article-title":"The impact of antisense oligonucleotide (ASO) therapeutics on the future of rare disease drug discovery","volume":"21","author":"Ruchi","year":"2026","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40259-025-00711-7","article-title":"The Fomivirsen, Patisiran, and Givosiran Odyssey: How the Success Stories May Pave the Way for Future Clinical Translation of Nucleic Acid Drugs","volume":"39","author":"Mansouri","year":"2025","journal-title":"BioDrugs"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40265-013-0042-2","article-title":"Mipomersen sodium: First global approval","volume":"73","author":"Hair","year":"2013","journal-title":"Drugs"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/S2352-3026(18)30021-8","article-title":"Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: A single-centre, open-label, dose-escalation, phase 1\/1b trial","volume":"5","author":"Ohanian","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.bpj.2022.05.030","article-title":"The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia","volume":"121","author":"Liu","year":"2022","journal-title":"Biophys. J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1158\/1078-0432.CCR-16-1317","article-title":"Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity","volume":"23","author":"Odate","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"314ra185","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"vi360","DOI":"10.1093\/annonc\/mdw378.04","article-title":"A phase 1b study (SCORES) assessing safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of durvalumab combined with AZD9150 or AZD5069 in patients with advanced solid malignancies and SCCHN","volume":"27","author":"Hong","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1182\/blood-2021-147567","article-title":"A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"138","author":"Roschewski","year":"2021","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cytogfr.2005.09.002","article-title":"Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009","volume":"17","author":"Schlingensiepen","year":"2006","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","article-title":"TGF-beta signaling in health and disease","volume":"186","author":"Massague","year":"2023","journal-title":"Cell"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Almansoori, M.E., Awad, A., Dhaiban, S., Alduhoori, M.T., Sharif, H., and Sajini, A. (2025). Recent progress in human telomerase structure and its therapeutic targeting. Front. Mol. Biosci., 12.","DOI":"10.3389\/fmolb.2025.1681988"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e3097","DOI":"10.1002\/jgm.3097","article-title":"Clinical advances of siRNA therapeutics","volume":"21","author":"Hu","year":"2019","journal-title":"J. Gene Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: State of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41587-023-02105-y","article-title":"RNA interference in the era of nucleic acid therapeutics","volume":"42","author":"Jadhav","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40120-020-00228-x","article-title":"Correction to: A Review of Patisiran (ONPATTRO(R)) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis","volume":"10","author":"Urits","year":"2021","journal-title":"Neurol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-021-01511-3","article-title":"Givosiran: A Review in Acute Hepatic Porphyria","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"20723","DOI":"10.1073\/pnas.1314307110","article-title":"Mutant KRAS is a druggable target for pancreatic cancer","volume":"110","author":"Gabai","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Zhang, H., Liao, X., and Tsai, H.I. (2023). KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1147676"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-25-3189","article-title":"A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D\/V in Locally Advanced Pancreatic Cancer","volume":"32","author":"Alagesan","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1158\/1535-7163.MCT-16-0541","article-title":"Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)","volume":"16","author":"Wagner","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/s41388-021-01714-8","article-title":"Oncogenic functions and therapeutic targeting of EphA2 in cancer","volume":"40","author":"Wilson","year":"2021","journal-title":"Oncogene"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13046-025-03391-x","article-title":"MicroRNA in cancer therapy: Breakthroughs and challenges in early clinical applications","volume":"44","author":"Tagliaferri","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Seyhan, A.A. (2024). Trials and Tribulations of MicroRNA Therapeutics. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031469"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s11658-019-0196-3","article-title":"Editorial focus: Understanding off-target effects as the key to successful RNAi therapy","volume":"24","author":"Bartoszewski","year":"2019","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA Versus miRNA as Therapeutics for Gene Silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K.K., and Shi, C. (2021). MicroRNA as an Important Target for Anticancer Drug Development. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.736323"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1021\/acsmaterialsau.2c00042","article-title":"Gold Nanoconjugates for miRNA Modulation in Cancer Therapy: From miRNA Silencing to miRNA Mimics","volume":"2","author":"Sousa","year":"2022","journal-title":"ACS Mater. Au"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e1768","DOI":"10.1002\/wrna.1768","article-title":"Innovative approaches in transforming microRNAs into therapeutic tools","volume":"14","author":"Samad","year":"2023","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/nar\/gkae141","article-title":"Chemical modification patterns for microRNA therapeutic mimics: A structure-activity relationship (SAR) case-study on miR-200c","volume":"52","author":"Garreau","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"200769","DOI":"10.1016\/j.omton.2024.200769","article-title":"Development of gemcitabine-modified miRNA mimics as cancer therapeutics for pancreatic ductal adenocarcinoma","volume":"32","author":"Yuen","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nbt0713-577","article-title":"First microRNA mimic enters clinic","volume":"31","author":"Bouchie","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10555-021-09973-3","article-title":"The comprehensive landscape of miR-34a in cancer research","volume":"40","author":"Li","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e3100","DOI":"10.1038\/cddis.2017.495","article-title":"Alternative mechanisms of miR-34a regulation in cancer","volume":"8","author":"Slabakova","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"11602","DOI":"10.1002\/cam4.5826","article-title":"Anti-tumor effects of miR-34a by regulating immune cells in the tumor microenvironment","volume":"12","author":"Yin","year":"2023","journal-title":"Cancer Med."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Bader, A.G. (2012). miR-34\u2014A microRNA replacement therapy is headed to the clinic. Front. Genet., 3.","DOI":"10.3389\/fgene.2012.00120"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1038\/leu.2012.110","article-title":"Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo","volume":"26","author":"Craig","year":"2012","journal-title":"Leukemia"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1158\/1078-0432.CCR-12-1708","article-title":"Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: In vitro and in vivo evidence","volume":"18","author":"Leone","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1158\/1535-7163.MCT-14-0209","article-title":"Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer","volume":"13","author":"Daige","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.21037\/tlcr.2017.12.01","article-title":"An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs)","volume":"7","author":"Viteri","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s12935-022-02754-0","article-title":"A review on the role of mir-16-5p in the carcinogenesis","volume":"22","author":"Khoshbakht","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pan.2012.02.008","article-title":"miR-15b and miR-16 induce the apoptosis of rat activated pancreatic stellate cells by targeting Bcl-2 in vitro","volume":"12","author":"Shen","year":"2012","journal-title":"Pancreatology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e42733","DOI":"10.1016\/j.heliyon.2025.e42733","article-title":"The role of miR-16 and miR-34a family in the regulation of cancers: A review","volume":"11","author":"Sadeghi","year":"2025","journal-title":"Heliyon"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"Pavlakis","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/s12276-023-01050-9","article-title":"MicroRNA: Trends in clinical trials of cancer diagnosis and therapy strategies","volume":"55","author":"Kim","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_145","first-page":"5913195","article-title":"Biological Function of MicroRNA193a-3p in Health and Disease","volume":"2017","author":"Grossi","year":"2017","journal-title":"Int. J. Genom."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"470","DOI":"10.18632\/oncotarget.28608","article-title":"INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death","volume":"15","author":"Duurland","year":"2024","journal-title":"Oncotarget"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-907X-3-1","article-title":"Inhibition of microRNA function by antimiR oligonucleotides","volume":"3","author":"Stenvang","year":"2012","journal-title":"Silence"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Lei, Y., Chen, L., Liu, J., Zhong, Y., and Deng, L. (2022). The MicroRNA-Based Strategies to Combat Cancer Chemoresistance via Regulating Autophagy. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.841625"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-20-3139","article-title":"Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo","volume":"27","author":"Anastasiadou","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40291-023-00641-6","article-title":"The Diagnostic and Prognostic Value of miR-155 in Cancers: An Updated Meta-analysis","volume":"27","author":"Wu","year":"2023","journal-title":"Mol. Diagn. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"103124","DOI":"10.1016\/j.arcmed.2024.103124","article-title":"Deficiency of miR-155 in Leukemic B-Cells Results in Cell Cycle Arrest and Deregulation of MIR155HG\/TP53INP1\/CDKN1A\/CCND1 network","volume":"56","author":"Golovina","year":"2025","journal-title":"Arch. Med. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/cdd.2014.28","article-title":"Oxidative stress-induced p53 activity is enhanced by a redox-sensitive TP53INP1 SUMOylation","volume":"21","author":"Peuget","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1182\/blood-2018-99-119861","article-title":"Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma","volume":"132","author":"Querfeld","year":"2018","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Di Martino, M.T., Gulla, A., Gallo Cantafio, M.E., Altomare, E., Amodio, N., Leone, E., Morelli, E., Lio, S.G., Caracciolo, D., and Rossi, M. (2014). In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089659"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.omtn.2022.02.005","article-title":"miR-221\/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review","volume":"27","author":"Arbitrio","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1038\/mtna.2016.36","article-title":"Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates","volume":"5","author":"Nielsen","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-023-01468-8","article-title":"Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: A first-in-human, phase 1, open-label, dose-escalation study","volume":"16","author":"Tassone","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12935-025-03812-z","article-title":"LncRNA16 inhibits pyroptosis and promotes platinum resistance in non-small cell lung cancer by sponging miRNA1827 to regulate MBD3\/GSDME expression","volume":"25","author":"Liu","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41419-020-02820-3","article-title":"Antisense oligonucleotides targeting lncRNA AC104041.1 induces antitumor activity through Wnt2B\/beta-catenin pathway in head and neck squamous cell carcinomas","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1038\/s41467-025-59886-w","article-title":"p53-inducible lncRNA LOC644656 causes genotoxic stress-induced stem cell maldifferentiation and cancer chemoresistance","volume":"16","author":"Tamura","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e2309298","DOI":"10.1002\/advs.202309298","article-title":"M2 Tumor-Associated Macrophages-Derived Exosomal MALAT1 Promotes Glycolysis and Gastric Cancer Progression","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"19502","DOI":"10.1038\/s41598-022-23802-9","article-title":"Knockdown of the long noncoding RNA PURPL induces apoptosis and sensitizes liver cancer cells to doxorubicin","volume":"12","author":"Berhane","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11427-023-2434-8","article-title":"Targeting lncRNA16 by GalNAc-siRNA conjugates facilitates chemotherapeutic sensibilization via the HBB\/NDUFAF5\/ROS pathway","volume":"67","author":"Liu","year":"2024","journal-title":"Sci. China Life Sci."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bph.17302","article-title":"Mitigating off-target effects of small RNAs: Conventional approaches, network theory and artificial intelligence","volume":"182","author":"Bereczki","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"126189","DOI":"10.1016\/j.ijpharm.2025.126189","article-title":"Small nucleic acid therapeutics: Delivery breakthroughs, clinical translation, and future paradigms in precision medicine","volume":"684","author":"Tang","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bcp.2018.11.013","article-title":"Comparison of different chemically modified inhibitors of miR-199b in vivo","volume":"159","author":"Duygu","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1517\/14712598.2015.1014794","article-title":"Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics","volume":"15","author":"Dobrovolskaia","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","article-title":"Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index","volume":"37","author":"Shen","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Nappi, F. (2024). Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073630"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e17571","DOI":"10.1002\/advs.202417571","article-title":"Recent Advances in mRNA Delivery Systems for Cancer Therapy","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Yang, X., Liang, Y., and Tong, S. (2023). Advancing cancer treatment: In vivo delivery of therapeutic small noncoding RNAs. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1297413"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-022-00272-w","article-title":"Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance","volume":"6","author":"Ge","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Tonello, S., Rolla, R., Tillio, P.A., Sainaghi, P.P., and Colangelo, D. (2025). Microenvironment and Tumor Heterogeneity as Pharmacological Targets in Precision Oncology. Pharmaceuticals, 18.","DOI":"10.3390\/ph18060915"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Antignani, A., Ho, E.C.H., Bilotta, M.T., Qiu, R., Sarnvosky, R., and FitzGerald, D.J. (2020). Targeting Receptors on Cancer Cells with Protein Toxins. Biomolecules, 10.","DOI":"10.3390\/biom10091331"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"101463","DOI":"10.1016\/j.omtm.2025.101463","article-title":"Lipid nanoparticles: Composition, formulation, and application","volume":"33","author":"Xu","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_177","first-page":"100305","article-title":"Exploring the landscape of Lipid Nanoparticles (LNPs): A comprehensive review of LNPs types and biological sources of lipids","volume":"8","author":"Alfutaimani","year":"2024","journal-title":"Int. J. Pharm. X"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Ramadan, E., Ahmed, A., and Naguib, Y.W. (2024). Advances in mRNA LNP-Based Cancer Vaccines: Mechanisms, Formulation Aspects, Challenges, and Future Directions. J. Pers. Med., 14.","DOI":"10.3390\/jpm14111092"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e2451008","DOI":"10.1002\/eji.202451008","article-title":"Lipid nanoparticle-mediated RNA delivery for immune cell modulation","volume":"54","author":"Kim","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"124519","DOI":"10.1016\/j.ijpharm.2024.124519","article-title":"DNA aptamer-conjugated lipid nanoparticle for targeted PTEN mRNA delivery to prostate cancer cells","volume":"662","author":"Kim","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"111612","DOI":"10.1016\/j.ejmech.2019.111612","article-title":"Application of glycosylation in targeted drug delivery","volume":"182","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jconrel.2020.03.006","article-title":"Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E\/low density lipoprotein receptor and the N-acetyl-d-galactosamine\/asialoglycoprotein receptor pathway","volume":"322","author":"Sato","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e2109256118","DOI":"10.1073\/pnas.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1039\/D3NH00145H","article-title":"Selective organ targeting nanoparticles: From design to clinical translation","volume":"8","author":"Li","year":"2023","journal-title":"Nanoscale Horiz."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: A phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","article-title":"First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement","volume":"3","author":"Tabernero","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Roma-Rodrigues, C., Rivas-Garcia, L., Baptista, P.V., and Fernandes, A.R. (2020). Gene Therapy in Cancer Treatment: Why Go Nano?. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030233"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"El-Ghazzi, N., Italiano, A., and Angeli, E. (2025). Gene expression silencing therapy in tumors, focus on gastrointestinal and genitourinary tumors. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1657040"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12958-023-01125-2","article-title":"Liposomal delivery of gene therapy for ovarian cancer: A systematic review","volume":"21","author":"Son","year":"2023","journal-title":"Reprod. Biol. Endocrinol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"120571","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications","volume":"601","author":"Guimaraes","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Tseu, G.Y.W., and Kamaruzaman, K.A. (2023). A Review of Different Types of Liposomes and Their Advancements as a Form of Gene Therapy Treatment for Breast Cancer. Molecules, 28.","DOI":"10.3390\/molecules28031498"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2019.01.045","article-title":"Aptamer-functionalized liposomes for targeted cancer therapy","volume":"448","author":"Moosavian","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Fulton, M.D., and Najahi-Missaoui, W. (2023). Liposomes in Cancer Therapy: How Did We Start and Where Are We Now. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076615"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/bs.pmbts.2023.12.010","article-title":"Advances in liposome-based delivery of RNA therapeutics for cancer treatment","volume":"204","author":"Sanati","year":"2024","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.biochi.2019.02.012","article-title":"Strategies in the design of endosomolytic agents for facilitating endosomal escape in nanoparticles","volume":"160","author":"Ahmad","year":"2019","journal-title":"Biochimie"},{"key":"ref_196","first-page":"H387","article-title":"Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice","volume":"273","author":"McLean","year":"1997","journal-title":"Am. J. Physiol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/sj.gt.3302777","article-title":"A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium","volume":"13","author":"Santel","year":"2006","journal-title":"Gene Ther."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Schultheis, B., Strumberg, D., Kuhlmann, J., Wolf, M., Link, K., Seufferlein, T., Kaufmann, J., Feist, M., Gebhardt, F., and Khan, M. (2020). Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib\/IIa Study. Cancers, 12.","DOI":"10.3390\/cancers12113130"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1200\/JCO.2013.55.0376","article-title":"First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors","volume":"32","author":"Schultheis","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"17802","DOI":"10.1021\/acsnano.2c08774","article-title":"Exosomes\u2500Nature\u2019s Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics","volume":"16","author":"Tenchov","year":"2022","journal-title":"ACS Nano"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Goo, J., Lee, Y., Lee, J., Kim, I.S., and Jeong, C. (2024). Extracellular Vesicles in Therapeutics: A Comprehensive Review on Applications, Challenges, and Clinical Progress. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16030311"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"e2201609","DOI":"10.1002\/advs.202201609","article-title":"Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications","volume":"9","author":"Yang","year":"2022","journal-title":"Adv. Sci."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Longo, A., Manganelli, V., Misasi, R., Riitano, G., Caglar, T.R., Fasciolo, E., Recalchi, S., Sorice, M., and Garofalo, T. (2025). Extracellular Vesicles in the Crosstalk of Autophagy and Apoptosis: A Role for Lipid Rafts. Cells, 14.","DOI":"10.3390\/cells14100749"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2019.07.003","article-title":"Exosomes and their role in tumorigenesis and anticancer drug resistance","volume":"45","author":"Milman","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"},{"key":"ref_207","first-page":"100390","article-title":"Overview of dendrimers as promising drug delivery systems with insight into anticancer and anti-microbial applications","volume":"10","author":"Fadaei","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"124573","DOI":"10.1016\/j.ijpharm.2024.124573","article-title":"Dendrimers as drug delivery systems for oncotherapy: Current status of promising applications","volume":"663","author":"Sueyoshi","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Rai, D.B., Medicherla, K., Pooja, D., and Kulhari, H. (2023). Dendrimer-Mediated Delivery of Anticancer Drugs for Colon Cancer Treatment. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030801"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"214493","DOI":"10.1016\/j.bioadv.2025.214493","article-title":"PEGylated dendrimers for precision cancer therapy: Advances in tumor targeting, drug delivery, and clinical translation","volume":"179","author":"Kesharwani","year":"2026","journal-title":"Biomater. Adv."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"e2304006","DOI":"10.1002\/smll.202304006","article-title":"Research Status of Dendrimer Micelles in Tumor Therapy for Drug Delivery","volume":"19","author":"Wang","year":"2023","journal-title":"Small"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/bloodadvances.2024013423","article-title":"Antileukemia efficacy of the dual BCL2\/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models","volume":"9","author":"Kannan","year":"2025","journal-title":"Blood Adv."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: From apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"13824","DOI":"10.1073\/pnas.1008051107","article-title":"Induction of complete and molecular remissions in acute myeloid leukemia by Wilms\u2019 tumor 1 antigen-targeted dendritic cell vaccination","volume":"107","author":"Cools","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.omtn.2023.07.009","article-title":"Role of long non-coding RNAs in cancer: From subcellular localization to nanoparticle-mediated targeted regulation","volume":"33","author":"Wei","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Zielinska, A., Carreiro, F., Oliveira, A.M., Neves, A., Pires, B., Venkatesh, D.N., Durazzo, A., Lucarini, M., Eder, P., and Silva, A.M. (2020). Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules, 25.","DOI":"10.3390\/molecules25163731"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s11671-021-03628-6","article-title":"Nanoparticles for Cancer Therapy: Current Progress and Challenges","volume":"16","author":"Gavas","year":"2021","journal-title":"Nanoscale Res. Lett."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Miron-Barroso, S., Correia, J.S., Frampton, A.E., Lythgoe, M.P., Clark, J., Tookman, L., Ottaviani, S., Castellano, L., Porter, A.E., and Georgiou, T.K. (2022). Polymeric Carriers for Delivery of RNA Cancer Therapeutics. Noncoding RNA, 8.","DOI":"10.3390\/ncrna8040058"},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Gagliardi, A., Giuliano, E., Venkateswararao, E., Fresta, M., Bulotta, S., Awasthi, V., and Cosco, D. (2021). Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.601626"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12272-020-01204-7","article-title":"Albumin nanoscience: Homing nanotechnology enabling targeted drug delivery and therapy","volume":"43","author":"Lamichhane","year":"2020","journal-title":"Arch. Pharm. Res."},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Begines, B., Ortiz, T., Perez-Aranda, M., Martinez, G., Merinero, M., Arguelles-Arias, F., and Alcudia, A. (2020). Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials, 10.","DOI":"10.3390\/nano10071403"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/bs.pmbts.2024.01.001","article-title":"Advances in the polymeric nanoparticulate delivery systems for RNA therapeutics","volume":"204","author":"Sristi","year":"2024","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","article-title":"Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles","volume":"464","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/jcp.36.5.539","article-title":"Transferrin receptors in human tissues: Their distribution and possible clinical relevance","volume":"36","author":"Gatter","year":"1983","journal-title":"J. Clin. Pathol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-024-02112-8","article-title":"Landscape of small nucleic acid therapeutics: Moving from the bench to the clinic as next-generation medicines","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"e003811","DOI":"10.1136\/jitc-2021-003811","article-title":"NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome","volume":"10","author":"Ishihara","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-23-1456","article-title":"Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I\/II Clinical Trial","volume":"29","author":"Kawai","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drudis.2017.09.018","article-title":"Locked nucleic acid: Modality, diversity, and drug discovery","volume":"23","author":"Hagedorn","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/gt.2010.133","article-title":"Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection","volume":"18","author":"Zhang","year":"2011","journal-title":"Gene Ther."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"101350","DOI":"10.1016\/j.mam.2025.101350","article-title":"The recent blooming of therapeutic aptamers","volume":"102","author":"Cesarini","year":"2025","journal-title":"Mol. Asp. Med."},{"key":"ref_231","first-page":"467","article-title":"Targeted therapy using nanotechnology: Focus on cancer","volume":"9","author":"Sanna","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cell.2020.02.001","article-title":"Targeting Strategies for Tissue-Specific Drug Delivery","volume":"181","author":"Zhao","year":"2020","journal-title":"Cell"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2013-03-493924","article-title":"The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization","volume":"123","author":"Hoellenriegel","year":"2014","journal-title":"Blood"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12943-023-01798-8","article-title":"Gold nanoparticles and gold nanorods in the landscape of cancer therapy","volume":"22","author":"Kesharwani","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"9823","DOI":"10.2147\/IJN.S279094","article-title":"A Review on the Synthesis and Functionalization of Gold Nanoparticles as a Drug Delivery Vehicle","volume":"15","author":"Amina","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Ferroni, C., Del Rio, A., Martini, C., Manoni, E., and Varchi, G. (2019). Light-Induced Therapies for Prostate Cancer Treatment. Front. Chem., 7.","DOI":"10.3389\/fchem.2019.00719"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1039\/C8NR04916E","article-title":"Nanoparticle heterogeneity: An emerging structural parameter influencing particle fate in biological media?","volume":"11","author":"Rabanel","year":"2019","journal-title":"Nanoscale"},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Cosma, M., Mocan, T., Delcea, C., Pop, T., Mosteanu, O., and Mocan, L. (2025). Gold Nanoparticles as Targeted Drug Delivery Systems for Liver Cancer: A Systematic Review of Tumor Targeting Efficiency and Toxicity Profiles. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26167917"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.molmed.2018.01.001","article-title":"Therapeutic Targeting of Long Non-Coding RNAs in Cancer","volume":"24","author":"Arun","year":"2018","journal-title":"Trends Mol. Med."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccell.2016.03.010","article-title":"Long Noncoding RNAs in Cancer Pathways","volume":"29","author":"Schmitt","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_241","doi-asserted-by":"crossref","unstructured":"Kafida, M., Karela, M., and Giakountis, A. (2024). RNA-Independent Regulatory Functions of lncRNA in Complex Disease. Cancers, 16.","DOI":"10.3390\/cancers16152728"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.molcel.2022.05.027","article-title":"Integrated lncRNA function upon genomic and epigenomic regulation","volume":"82","author":"Herman","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense Oligonucleotide Therapies for Neurodegenerative Diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/bs.acc.2019.08.003","article-title":"Long noncoding RNAs in cancer: From discovery to therapeutic targets","volume":"95","author":"Choudhari","year":"2020","journal-title":"Adv. Clin. Chem."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ncrna.2024.03.014","article-title":"Exosomal long non-coding RNAs in cancer: Interplay, modulation, and therapeutic avenues","volume":"9","author":"Marima","year":"2024","journal-title":"Noncoding RNA Res."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41576-024-00693-2","article-title":"Targeting and engineering long non-coding RNAs for cancer therapy","volume":"25","author":"Coan","year":"2024","journal-title":"Nat. Rev. Genet."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1080\/15476286.2015.1038012","article-title":"Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function","volume":"12","author":"Cabanski","year":"2015","journal-title":"RNA Biol."},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Pozdniakova, N., Generalov, E., Shevelev, A., and Tarasova, O. (2025). RNA Therapeutics: Delivery Problems and Solutions-A Review. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17101305"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12032-024-02534-y","article-title":"Advancements in long non-coding RNA-based therapies for cancer: Targeting, delivery, and clinical implications","volume":"41","author":"Ammad","year":"2024","journal-title":"Med. Oncol."},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"Roffo, F., Orlandella, F.M., Luciano, N., Salvatore, G., and Torino, E. (2026). Lipid-Polymer Nanoparticles (LiPoNs) Mediated Codelivery of AntimiR-21 and Gadolinium Chelate in Triple Negative Breast Cancer Theranostics. Bioengineering, 13.","DOI":"10.3390\/bioengineering13020209"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2497\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:39:52Z","timestamp":1785836392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":253,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152497"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152497","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]}}}